123 related articles for article (PubMed ID: 26273372)
1. Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma.
Li Z; Jiang L; Bai H; Wang Z; Zhao J; Duan J; Yang X; An T; Wang J
Thorac Cancer; 2015 May; 6(3):269-74. PubMed ID: 26273372
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma.
Shan L; Qiu T; Ling Y; Guo L; Zheng B; Wang B; Li W; Li L; Ying J
PLoS One; 2015; 10(6):e0130447. PubMed ID: 26102513
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
Marchetti A; Felicioni L; Malatesta S; Grazia Sciarrotta M; Guetti L; Chella A; Viola P; Pullara C; Mucilli F; Buttitta F
J Clin Oncol; 2011 Sep; 29(26):3574-9. PubMed ID: 21825258
[TBL] [Abstract][Full Text] [Related]
5. Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF-mutation status?
Ma SS; Wang RR; Peng Q; Liu Y; Qian JY; Li MJ; Li K; Huang ZY; Wu LL; Xie D
Thorac Cancer; 2024 Mar; 15(9):715-721. PubMed ID: 38362771
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E Mutations in Endometrial Adenocarcinoma.
He M; Breese V; Hang S; Zhang C; Xiong J; Jackson C
Diagn Mol Pathol; 2013 Mar; 22(1):35-40. PubMed ID: 23370429
[TBL] [Abstract][Full Text] [Related]
7. The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
Yousem SA; Nikiforova M; Nikiforov Y
Am J Surg Pathol; 2008 Sep; 32(9):1317-21. PubMed ID: 18636014
[TBL] [Abstract][Full Text] [Related]
8. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
9. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S
Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121
[TBL] [Abstract][Full Text] [Related]
10. EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF
Zeng R; Luo L; Sun X; Bao Z; Du W; Dai R; Tang W; Gao B; Xiang Y
Cancer Drug Resist; 2021; 4(4):1019-1027. PubMed ID: 35582379
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
[TBL] [Abstract][Full Text] [Related]
12. High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles.
Chen D; Huang JF; Xia H; Duan GJ; Chuai ZR; Yang Z; Fu WL; Huang Q
Anal Bioanal Chem; 2014 Apr; 406(9-10):2477-87. PubMed ID: 24500755
[TBL] [Abstract][Full Text] [Related]
13. Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma.
Yang Y; Meng Y; Zhang H; Shen X; Li R; Yu L; Liu B; Wang L
Oncol Lett; 2018 Mar; 15(3):3295-3304. PubMed ID: 29467863
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations.
Zhang H; Bai H; Yang X; Zhong J; An T; Zhao J; Wang J
Thorac Cancer; 2016 Jan; 7(1):24-31. PubMed ID: 26813477
[TBL] [Abstract][Full Text] [Related]
15. Validation of Immunohistochemistry for the Detection of
Gow CH; Hsieh MS; Lin YT; Liu YN; Shih JY
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234388
[No Abstract] [Full Text] [Related]
16. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.
Thiel A; Moza M; Kytölä S; Orpana A; Jahkola T; Hernberg M; Virolainen S; Ristimäki A
Hum Pathol; 2015 Feb; 46(2):169-75. PubMed ID: 25442222
[TBL] [Abstract][Full Text] [Related]
17. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.
Warth A; Penzel R; Lindenmaier H; Brandt R; Stenzinger A; Herpel E; Goeppert B; Thomas M; Herth FJ; Dienemann H; Schnabel PA; Schirmacher P; Hoffmann H; Muley T; Weichert W
Eur Respir J; 2014 Mar; 43(3):872-83. PubMed ID: 23988776
[TBL] [Abstract][Full Text] [Related]
18. BRAF-mutations in non-small cell lung cancer.
Brustugun OT; Khattak AM; Trømborg AK; Beigi M; Beiske K; Lund-Iversen M; Helland Å
Lung Cancer; 2014 Apr; 84(1):36-8. PubMed ID: 24552757
[TBL] [Abstract][Full Text] [Related]
19. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Gautschi O; Milia J; Cabarrou B; Bluthgen MV; Besse B; Smit EF; Wolf J; Peters S; Früh M; Koeberle D; Oulkhouir Y; Schuler M; Curioni-Fontecedro A; Huret B; Kerjouan M; Michels S; Pall G; Rothschild S; Schmid-Bindert G; Scheffler M; Veillon R; Wannesson L; Diebold J; Zalcman G; Filleron T; Mazières J
J Thorac Oncol; 2015 Oct; 10(10):1451-7. PubMed ID: 26200454
[TBL] [Abstract][Full Text] [Related]
20. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P
Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
